Inhibikase Therapeutics (IKT) Current Assets (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Current Assets data on file, last reported at $172.2 million in Q1 2026.

• Current Assets for Q1 2026 came in at $172.2 million, up 82.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $172.2 million (up 82.85% YoY), and the FY2025 annual result was $180.1 million, up 82.94% from the prior year.
• Current Assets slipped to $172.2 million in Q1 2026 per IKT's latest filing, from $180.1 million in the prior quarter.
• Over five years, Current Assets peaked at $180.1 million in Q4 2025 and troughed at $4.2 million in Q3 2024.
• A 5-year average of $56.5 million and a median of $27.8 million in 2022 frame the typical range for Current Assets.
• The sharpest annual moves came in 2024 and 2025: Current Assets slumped 76.13% in 2024, then soared 1774.34% in 2025.
• A 5-year view of Current Assets shows it stood at $24.4 million in 2022, then slumped by 41.69% to $14.2 million in 2023, then surged by 592.78% to $98.5 million in 2024, then soared by 82.94% to $180.1 million in 2025, then declined by 4.4% to $172.2 million in 2026.
• Business Quant data shows IKT's Current Assets at $172.2 million in Q1 2026, $180.1 million in Q4 2025, and $78.5 million in Q3 2025.